Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/21/2012 | 11:46am CET

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.

MAIN FACTS:

-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
Stocks mentioned in the article
ChangeLast1st jan.
MERCK AND COMPANY 0.55% 54.87 Delayed Quote.-3.02%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
02/23MERCK AND : Ferring Pharmaceuticals and MSD Announce Completion of Largest Clini..
AQ
02/23ASTRAZENECA : Lynparza CHMP for ovarian cancer maintainance
AQ
02/23MERCK AND : LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion in Platinum-S..
BU
02/23MERCK AND : plans to boost its immunotherapy drugs with tumor-bursting viruses
AQ
02/23MERCK AND : buys cancer-killing virus firm Viralytics for $394m
AQ
02/22MERCK AND : Ferring Pharmaceuticals and Merck Announce Completion of Largest Cli..
PU
02/22MERCK AND : Viralytics Announce Acquisition Agreement Expanding Merck's Leading ..
AQ
02/22MERCK AND : inks $394M takeover of oncolytic virus play Viralytics
AQ
02/21Merck to buy virus-based cancer drug firm Viralytics for $394 million
RE
02/21MERCK AND : to Buy Australia's Viralytics for $394 Million
DJ
More news
News from SeekingAlpha
02/23Arcus Biosciences Files To Raise $100 Million In IPO 
02/23European advisory group backs the use of Merck's Isentress for newborns 
02/23European advisory group backs expanded use for AstraZeneca's Lynparza 
02/22ACETO : Collapsing Generic Drug Pricing Brings Risk Of Covenant Violations 
02/21YOUR DAILY PHARMA SCOOP : Portola Update, Wave Life Sciences To Collaborate With.. 
Financials ($)
Sales 2018 41 703 M
EBIT 2018 13 718 M
Net income 2018 8 465 M
Debt 2018 13 842 M
Yield 2018 3,52%
P/E ratio 2018 16,80
P/E ratio 2019 13,51
EV / Sales 2018 3,90x
EV / Sales 2019 3,75x
Capitalization 149 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 66,2 $
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-3.02%148 618
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%224 221
PFIZER-1.27%213 155
ROCHE HOLDING LTD.-9.41%207 327
AMGEN4.91%132 428